Skip to main content
Apyx Medical Corp logo

Apyx Medical Corp — Investor Relations & Filings

Ticker · APYX ISIN · US0323472052 LEI · 5299009QZVYUYO082S45 US Manufacturing
Open in API
Filings indexed 969 across all filing types
Latest filing 2015-03-17 Capital/Financing Update
Country US United States of America
Listing US APYX

About Apyx Medical Corp

https://apyxmedical.com/

Apyx Medical Corporation is an advanced energy technology company that develops, manufactures, and markets innovative products for surgical and cosmetic markets. The company's proprietary Helium Plasma Platform, which is the foundation for its Renuvion® and J-Plasma® brands, utilizes a unique combination of helium plasma and radiofrequency (RF) energy. These systems are designed to deliver controlled energy for the cutting, coagulation, and ablation of soft tissue, with a primary focus on aesthetic procedures for skin tightening and body contouring. Apyx Medical, formerly Bovie Medical, leverages its expertise in energy-based waveforms to provide transformative solutions for surgeons and their patients.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about a material definitive agreement involving issuance of Series B Convertible Preferred Stock, amendments to articles of incorporation, and a public offering of common stock. These disclosures relate to financing activities and capital structure changes. There are no comprehensive financial statements or management discussion and analysis typical of annual or interim reports. The document is not a proxy statement, earnings release, or legal proceeding report. Given the focus on financing transactions and capital changes, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2015-03-17 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(2) under a registration statement, describing an offering of 4,800,000 shares of common stock by Bovie Medical Corporation. It includes detailed information about the offering price, underwriting discounts, use of proceeds, risk factors, and company background. The document is clearly related to a capital raising event and financing activity. It is not an annual or quarterly report, earnings release, or any other type of report. The presence of underwriting details and offering terms indicates this is a Capital/Financing Update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2015-03-12 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 12, 2015, by Bovie Medical Corporation. It reports the entry into a material definitive agreement related to an underwriting agreement for a public offering of common stock. The document includes details about the offering size, price, and expected proceeds, as well as references to related exhibits such as the underwriting agreement and legal opinion. There is also a press release attached announcing the pricing of the offering. The content focuses on a financing event and capital raising activity. Given the nature of the information—public offering of shares, underwriting agreement, and related disclosures—this filing fits the category of Capital/Financing Update (CAP). The document is not an earnings release, annual report, or other types of filings. The length and detail confirm it is not merely an announcement of a report but a substantive filing about financing activity.
2015-03-12 English
PROSPECTUS
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement and accompanying prospectus related to a securities offering by Bovie Medical Corporation. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and company background. The document is filed pursuant to Rule 424(b)(5) under a registration statement, which is a typical format for capital raising disclosures. This type of document is specifically related to capital/financing activities, such as issuing new shares to the public. It is not an annual or quarterly report, earnings release, or any other type of report. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2015-03-11 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an entry into a material definitive agreement involving issuance of Series B Convertible Preferred Stock, amendments to articles of incorporation, and a press release about a proposed public offering. There are no financial statements or detailed financial performance data presented, only disclosures about financing transactions and corporate governance changes related to capital structure. This fits the category of Capital/Financing Update (CAP) as it involves issuance of preferred stock, exchange agreements, and registration rights related to financing activities. The document is not an Annual Report, Earnings Release, or Management Report, nor is it a simple announcement of a report publication. Therefore, the appropriate classification is CAP with high confidence.
2015-03-11 English
SC 13G/A
Major Shareholding Notification
2015-03-02 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.